| Document |
Document Title |
|
WO/2024/093907A1 |
Provided are a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The compound of formula (I) is contained inside a nucleotide, or at a 5' end and/or a 3' end, and is used for improving the ...
|
|
WO/2024/088237A1 |
Compounds of a general formula, the use thereof, and an organic electroluminescent device containing same. The compounds have structures represented by formula (1), wherein the dotted line represents ring A being an optional structure; w...
|
|
WO/2024/091450A1 |
The present disclosure relates to compounds for treating cancer. The compounds may prevent conversion of non-stem cancer cells into cancer-initiating cells caused by radiation treatment.
|
|
WO/2024/091943A2 |
The present invention relates to deuterated etifoxine compositions and methods for administration without autoinduction of metabolism in the treatment of a variety of diseases, disorders, or conditions.
|
|
WO/2024/086259A1 |
Described herein are novel methods of synthesizing 2-amino-5-chloro-N,3- dimethylbenzamide. Compounds prepared by the methods disclosed herein are useful for preparation of certain anthranilamide compounds that are of interest as insecti...
|
|
WO/2024/073587A1 |
Compounds and methods for inhibiting Nrf2 by activating KEAP1.
|
|
WO/2024/072930A1 |
D3R selective partial agonists and their use in treating substance use disorders alone or in combination with affective disorders are disclosed. These substance use disorders include psychostimulant use disorder (PSUD). Compounds include...
|
|
WO/2024/046223A1 |
The present application relates to substituted indazole formamide derivatives, a preparation method therefor, and the use of a pharmaceutical composition containing the derivatives or deuterated derivatives in medicines. Specifically, th...
|
|
WO/2024/047227A1 |
The present invention relates to compounds of Formula (I) and (II) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The present invention also relates to pharmaceutical c...
|
|
WO/2024/042471A1 |
Described herein are processes for the synthesis of P2X3 antagonists, wherein the P2X3 antagonist is methyl (S)-2-((2-(2,6-difluoro-4- (methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)
methyl)morpholine-4-carboxylate (Compound...
|
|
WO/2024/038436A1 |
The present invention relates to the preparation of cyantraniliprole, comprising the preparation of 8-methyl-2,4-dioxo-l,4-dihydro-2H-benzo[d][l,3]oxazine-6-car
bonitrile key intermediate via 2-amino-5-((hydroxyimino)methyl)-3-methylbenz...
|
|
WO/2024/028423A1 |
The present invention relates to an efficient and industrially applicable process for the preparation of 2-substituted morpholine derivatives such as viloxazine and to intermediates useful therefor.
|
|
WO/2024/028604A1 |
The present invention relates to compounds of formula (I) as prostaglandin E2 receptor 4 (EP4) agonists for use in methods of treatment of gastrointestinal and pulmonary diseases or disorders. The present disclosure provides exemplary co...
|
|
WO/2024/031051A1 |
Provided herein are ionizable lipids, compositions comprising the ionizable lipids, and methods of making and using the same. The ionizable lipids provided herein can be formulated in lipid compositions for the delivery of macromolecules...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/024648A1 |
One aspect of the present invention relates to an organic pigment composition containing: an organic pigment (A) that changes in color when hydrolyzed, and that emits fluorescence when excited by excitation light having a wavelength of 4...
|
|
WO/2024/025881A2 |
Stimulator of Interferon Genes (STING) modulators and their use for treating a disease, disorder, or condition associated with STING.
|
|
WO/2024/024833A1 |
Provided are: a resin composition containing a cyclized resin precursor and a compound B in which the thermal decomposition start temperature at which an amine is generated is equal to or less than 200°C, as measured by means of the sim...
|
|
WO/2023/280638A9 |
The application relates to vinyl thianthrenium compounds Vinyl- TT+X- of the Formula (I), a process for preparing the same and the use thereof for vinylating organic compounds.
|
|
WO/2024/002263A1 |
Disclosed are a series of amino-substituted heteroaryl and use thereof, and in particular, disclosed are a compound represented by formula (IV) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/250002A1 |
The present disclosure is concerned with benzothiazone compounds that are capable of inhibiting Tau-SH3 signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders...
|
|
WO/2023/245297A1 |
There are provided ferroptosis inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a disease or disorder associated with ferroptosis, such as a neurodegenerative disease or ischemic reperfu...
|
|
WO/2023/250107A1 |
The present disclosure relates generally to methods for the preparation of Compound (I-1): I-1 or a stereoisomer or mixture of stereoisomers thereof, or salt of each thereof, as well as compounds and salts which are useful in the synthes...
|
|
WO/2023/248154A1 |
The present invention relates to an improved process for the preparation of viloxazine or its pharmaceutically acceptable salts such as the hydrochloride salt. Further, the present invention relates to a novel compound designated herein ...
|
|
WO/2023/238718A1 |
Provided are: a difluorobutene acid amide compound having an excellent controlling effect against harmful weeds; and an herbicidal composition thereof. The herbicidal composition contains a difluorobutene acid amide compound represented ...
|
|
WO/2023/217119A1 |
Disclosed herein is a diclofenac prodrug represented by formula (I), wherein each of the substituents is given the definition as set forth in the Specification and Claims. Also disclosed is a method for alleviating arthritis, which inclu...
|
|
WO/2023/218203A1 |
The present invention relates to compounds that are MALT1 inhibitors. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical c...
|
|
WO/2023/210623A1 |
The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
|
|
WO/2023/208005A1 |
Compounds of formula (I), formula (II) or formula (III), the preparation method thereof, pharmaceutical compositions comprising the compounds, and the pharmaceutical uses for the treatment of diseases or disorders are provided.
|
|
WO/2023/208170A1 |
Provided are a protease inhibitor, a method for preparing same, and use thereof. The protease inhibitor can be combined with one or more pharmaceutically acceptable excipients or one or more other active ingredients to be used as a PLpro...
|
|
WO/2023/205450A1 |
Provided herein are compounds, compositions, and methods for rapid isolation of nucleic acids from a sample.
|
|
WO/2023/199091A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. [Solving Means] A compound represented by the formula (I) is useful as an agent for the prophylaxis or treatment of narcolepsy.
|
|
WO/2023/186881A1 |
The invention relates to p38 MAP kinase inhibitors of formula (I) as shown in the description for use in the treatment of colorectal cancer. Further, the invention relates to p38 MAP kinase inhibitors specifically mentioned in the descri...
|
|
WO/2023/178035A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/177845A1 |
Provided here are methods of making derivatives and prodrugs of substituted morpholines or pharmaceutically acceptable salts thereof. Further provided are methods of making derivatives and prodrugs of substituted morpholines having the f...
|
|
WO/2023/173053A1 |
The present disclosure provides MEK inhibitors, compositions thereof, and methods of using the same.
|
|
WO/2023/171801A1 |
Provided are crystals of a vitamin D derivative represented by formula (1) or crystals of a solvate of a vitamin D derivative represented by formula (1). Such crystals are useful as a pharmaceutical for promoting induction of differentia...
|
|
WO/2023/171665A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
|
WO/2023/165943A1 |
The invention relates to novel compounds having the general formula (I), wherein R1, R10, Rx, Ry, Y, m, and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/163533A1 |
The present invention relates to a pure organic molecule (without a metal center) and a use of the pure organic molecule as an emitter or absorber in an optoelectronic device. According to the present invention, the pure organic molecule...
|
|
WO/2023/152346A1 |
The present invention relates to compounds that are suitable for use in electronic devices, and to electronic devices, more particularly organic electroluminescent devices, containing these compounds.
|
|
WO/2023/149548A1 |
The present invention addresses the problem of providing a novel pharmaceutical composition, and in particular, a novel anti-cancer pharmaceutical composition, and a novel compound used in said pharmaceutical composition. The present i...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2023/143386A1 |
The present invention relates to an aromatic ring-fused heterocyclic ring compound as a potassium channel regulator, and the preparation therefor and the use thereof. Specifically, the compound of the present invention has a structure as...
|
|
WO/2023/146975A1 |
Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods of preparation thereof, wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a co...
|
|
WO/2023/144228A1 |
The present invention relates to a copolymer having several azide functionalities that can be prepared by cationic ring opening polymerisation. The copolymer comprises a first monomer unit and a second monomer unit which are different fr...
|
|
WO/2023/132369A1 |
Provided is a compound able to activate Nrf2 and represented by formula (1), a salt thereof, or a solvate of these. Formula (1) (In the formula, Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2, and Ra3 are each independently selected from...
|
|
WO/2023/120452A1 |
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by fo...
|
|
WO/2023/098740A1 |
The present invention belongs to the technical field of photoelectric materials, and particularly relates to an organic room-temperature electrophosphorescent material, and a preparation method therefor and an organic electroluminescent ...
|
|
WO/2023/099462A1 |
The present invention relates to amine-containing vinyldisiloxane compounds which are useful in the manufacture of elastomeric polymers that can be used in rubber articles such as tires. The present invention further relates to a process...
|
